{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T07:40:06Z","timestamp":1746344406318,"version":"3.40.4"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T00:00:00Z","timestamp":1611273600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"crossref","award":["no"],"award-info":[{"award-number":["no"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Thymic carcinoma is a rare malignancy, and platinum-based chemotherapy has not previously been established as a standard treatment for advanced or metastatic thymic carcinoma. With the breakthrough and progress of immunotherapy, the possibility of curing thymic carcinoma has greatly increased. Some clinical trials have reported that compared with traditional platinum-based chemotherapy, the use of programmed death 1 and programmed death ligand 1 inhibitors alone can benefit patients and effectively prolong their overall survival. We compare the efficacy of single immunotherapy with traditional platinum-based chemotherapy in a systematic review and meta-analysis to provide a reliable basis for clinicians.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Pubmed (Medline), Web of Science, Embase, Cochrane Central Register of Controlled Trials, and Google Scholar will be searched for relevant randomised controlled trials, quasi- randomised controlled trials, and Hi-Q(high quality) prospective cohort trials published or unpublished in any language before March 1, 2021. Subgroup analysis will be performed in tumor pathological stage and ethnicity. INPLASY registration number: INPLASY2020110060.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The results of this study will be published in a peer-reviewed journal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The results of this systematic review and meta-analysis will provide a basis for clinicians to formulate the best chemotherapy regimen for patients, as well as a research clue for clinical researchers in this field. The results of this study will expand the treatment options for thymic carcinoma, but due to the nature of the disease and intervention, large sample clinical trials are not abundant, so we will include some high-quality small sample trials, which may cause high heterogeneity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INPLASY registration number:<\/jats:title>\n            <jats:p>INPLASY2020110060<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023802","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T13:32:38Z","timestamp":1611408758000},"page":"e23802","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Immunotherapy vs platinum for advanced or metastatic thymic carcinoma"],"prefix":"10.1097","volume":"100","author":[{"given":"Jiekun","family":"Qian","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangwei","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The First Affiliated Hospital, Fujian Medical University, Fuzhou, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1369-6938","authenticated-orcid":false,"given":"Chun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Fujian Medical University Union Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,1,22]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1016\/j.ejca.2011.08.008","article-title":"Rare cancers are not so rare: the rare cancer burden in Europe","volume":"47","author":"Gatta","year":"2011","journal-title":"Eur J Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ejcts\/ezv239","article-title":"Long-term outcome and prognostic factors of surgically treated thymic carcinoma: results of 306 cases from a Japanese nationwide database study","volume":"49","author":"Hishida","year":"2016","journal-title":"Eur J Cardio-thorac Surg"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"S1749","DOI":"10.1097\/JTO.0b013e31821ea5f7","article-title":"Chemotherapy definitions and policies for thymic malignancies","volume":"6","author":"Girard","year":"2011","journal-title":"J Thorac Oncol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J Clin Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2019.03.012","article-title":"Single-arm, multicentre, phase II trial of nivolumab for unresectable or thymic carcinoma: PRIMER study","volume":"113","author":"Katsuya","year":"2019","journal-title":"Eur J Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"S346","DOI":"10.1016\/j.jtho.2018.08.297","article-title":"OA11.05 phase II study of sunitinib in patients with thymic carcinoma previously treated with platinum-based chemotherapy (KOSMIC Trial)","volume":"13","author":"Kim","year":"2018","journal-title":"J Thorac Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"562","DOI":"10.6004\/jnccn.2013.0072","article-title":"Thymomas and thymic carcinomas: clinical practice guidelines in oncology","volume":"11","author":"Ettinger","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1523-5394.2000.83001.x","article-title":"ACS cancer facts and figures","volume":"8","author":"Houts","year":"2000","journal-title":"Cancer Pract"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","article-title":"Molecular pathways: next-generation immunotherapyinhibiting programmed death-ligand 1 and programmed death-1","volume":"18","author":"Chen","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with Lambrolizumab (Anti\u2013PD-1) in Melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial: the Lancet","volume":"384","author":"Caroline","year":"2014","journal-title":"Lancet"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Br Med J"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ (Clinical research ed)"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ (Clinical research ed)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023802","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T07:00:38Z","timestamp":1746342038000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023802"}},"subtitle":["A protocol for systematic review and meta analysis"],"short-title":[],"issued":{"date-parts":[[2021,1,22]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023802","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,1,22]]},"assertion":[{"value":"2020-11-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}